MedTech Acquisition Corp
MedTech Acquisition Corp is listed today as TriSalus Life Sciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2025 | $22 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Jun 2023 | $18 M | Private placement after listing | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
MedTech Acquisition Corp chose not to state its revenue in its newest notice of a funding round (May 2025).
SEC Form D · May 2025
The industry group it chose in its notices: Other Health Care.
SEC Form D · May 2025
That is all the official record says: MedTech Acquisition Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of MedTech Acquisition Corp are on record.
Investors#
1 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Frankenius Equity AB | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding TriSalus Life Sciences, Inc. shares, as of Sep 30, 2026.
- First Light Asset Management, LLC$32 M12.02%
- BlackRock, Inc.$11 M4.23%
- Vanguard Capital Management LLC$7 M2.79%
- Cerity Partners LLC$7 M2.60%
- Geode Capital Management, LLC$5 M1.82%
- Gilder Gagnon Howe & Co LLC$4 M1.33%
- State Street Corp$3 M1.08%
- Kennedy Capital Management LLC$3 M1.01%
- Thompson Siegel & Walmsley LLC$2 M0.86%
- Nantahala Capital Management, LLC$2 M0.81%
- White Pine Capital LLC$2 M0.81%
- Morgan Stanley$2 M0.68%
- Northern Trust Corp$2 M0.57%
- Invesco Ltd.$2 M0.57%
- Vanguard Portfolio Management LLC$1 M0.50%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian F. Cox | Executive officer | May 2025 |
| James Young | Executive officer | May 2025 |
| Jennifer J. Stevens | Executive officer | May 2025 |
| Jodi J. Devlin | Executive officer | May 2025 |
| Mary Szela | Executive officer | May 2025 |
| Richard J. Marshak | Executive officer | May 2025 |
| Christopher C. Dewey | Chief Executive Officer | Jun 2023 |
| David J. Matlin | Chief Financial Officer | Jun 2023 |
| Robert H. Weiss | Chief Administrative Officer and Secretary | Jun 2023 |
| Andrew F. von Eschenbach | Director | May 2025 |
| Arjun F. Desai | Director | May 2025 |
| David J. Matlin | Director | May 2025 |
| Gary F. Gordon | Director | May 2025 |
| Kerry F. Hicks | Director | May 2025 |
| Mary Szela | Director | May 2025 |
| Mats J. Wahlstrom | Director | May 2025 |
| Sean Murphy | Director | May 2025 |
| William F. Valle | Director | May 2025 |
| Christopher C. Dewey | Chief Executive Officer | Jun 2023 |
| David L. Treadwell | Director | Jun 2023 |
| Karim Karti | Chairman | Jun 2023 |
| Manuel H. Aguero | Director | Jun 2023 |
| Martin H. Roche | Director | Jun 2023 |
| Thierry H. Thaure | Director | Jun 2023 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.